CAPÍTULO 6: Clinimetría en pacientes con espondiloartritis axial
Resumen
El tratamiento de la espondiloartritis axial (EspAax) ha avanzado mucho en los últimos años. El desarrollo de nuevas opciones terapéuticas representa un gran avance para esta enfermedad. Por lo tanto, resulta imprescindible contar con herramientas de medición de los diferentes aspectos de la enfermedad como actividad, funcionalidad, calidad de vida, entre otros aspectos tanto para estudios de investigación como para la práctica diaria. A continuación, se describen los instrumentos más importantes para la evaluación de pacientes con EspAax.Citas
I. Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol.2022;18(4):205-216.
II. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
III. Citera G, Maldonado Cocco J, Moroldo M, Burgos-Vargas R, Anaya J, López I, et al. Validación de la versión en español de los cuestionarios de capacidad funcional (BASFI) y actividad de la enfermedad (BASDAI) en pacientes con Espondilitis Anquilosante en cuatro países latinoamericanos. Rev Argent Reumatol. 1999;10(Supl 1):25 [abstract].
IV. Machado P, Landewé R. Spondyloarthritis: Is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol. 2013;9(7):388-90.
V. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455-61.
VI. Kwon OC, Park MC. BASDAI cut-off values corresponding to ASDAS cut-off values. Rheumatology (Oxford). 2022;30;61(6):2369-2374.
VII. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18-24.
VIII. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-8.
IX. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47-53.
X. Machado PM, Landewé R, Heijde DV; Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539-1540.
XI. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis. 2011;70(8):1375-81.
XII. Marona J, Sepriano A, Rodrigues-Manica S, Pimentel-Santos F, Mourão AF, Gouveia N, et al. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. RMD Open. 2020;6(1):e001145.
XIII. Nam B, Koo BS, Lee TH, Shin JH, Kim JJ, Lee S, et al. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study. BMC Musculoskelet Disord. 2021;22(1):140.
XIV. Benavent D, Capelusnik D, Ramiro S, Molto A, López-Medina C, Dougados M, et al. Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study. RMD Open. 2022 ;8(2):e002514.
XV. Sommerfleck FA, Schneeberger EE, Buschiazzo EE, Maldonado Cocco JA, Citera G. A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis. Clin Rheumatol. 2012;31(11):1599-603.
XVI. Schneeberger EE, Zamora N, Citera G. SASDAS (simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis. Clin Rheumatol. 2016;35(11):2865-2866.
XVII. Capelunsik D, Schneeberger EE, Citera G. SASDAS: a practical tool to measure disease activity in axSpa patients. Comments on "a prospective study of novel disease activity indices for ankylosing spondylitis. Rheumatol Int. 2021;41(4):839-840.
XVIII. Solmaz D, Yildirim T, Avci O, Tomas N, Akar S. Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS). Clin Rheumatol. 2016;35(7):1753-8.
XIX. Salaffi F, Ciapetti A, Carotti M, Gasparini S, Citera G, Gutierrez M. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. Health Qual Life Outcomes. 2014 22;12:129.
XX. Bansal N, Duggal L, Jain N. Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian ankylosing spondylitis patients. J Clin Diagn Res. 2017;11(9):OC06-OC09.
XXI. Schneeberger EE, Citera G, de Leon DP, Szumski AE, Kwok K, Cutri M, et al. Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) vs. ASDAS. A post hoc analysis of a randomized controlled trial. J Rheumatol. 2022;49(10):1100-1108.
XXII. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
XXIII. Marengo MF, Schneeberger E.E, Gagliardi S, Maldonado Cocco JA, Citera G. Determinantes de discapacidad funcional en pacientes con espondilitis anquilosante en Argentina. Rev Argent Reumatol. 2009;20(3):20-25.
XXIV. Ward MM, Weisman MH, Davis JC Jr, Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum. 2005; 15;53(5):710-7.
XXV. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. Rheumatol; 2002;29:1420-5.
XXVI. Marengo MF, Schneeberger EE, Citera G, Maldonado Cocco JA. Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 2008;14(5):273-277.
XXVII. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694 -8.
XXVIII. Van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489-93.
XXIX. Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S47-58.
XXX. Daltroy LH, Larson MG, Roberts NW, Liang MH. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol. 1990;17(7):946-50.
XXXI. Gossec L, Solano C, Paternotte S, Beauvais C, Gaudin P, von Krause G,et al (2012) Elaboration and validation of a ques- tionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement. Clin Exp Rheumatol 30(4):505-513.
XXXII. Sommerfleck FA, Schneeberger EE, Orozco MC, Zamora N, Landi M, Citera G. Validation and cultural adaptation of the qualisex questionnaire in patients with axial spondyloarthritis in Argentina. Rheumatol Int. 2018;38(11):2103-2109.
XXXIII. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
XXXIV. EuroQol Group. EuroQol a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
XXXV. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62(1):20-6.
XXXVI. Marengo MF, Schneeberger EE, Gagliardi S, Maldonado Cocco JA, Citera G. Determinantes de discapacidad funcional en pacientes con espondilitis anquilosante. Rev Argent Reumatol. 2009;20(3):20-25.
XXXVII. Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74(5):830-5.
XXXVIII. Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77(9):1311-7.
XXXIX. Duarte V, Kiltz U, Navarro-Compán V, Lloves N, Crespo Amaya G, Ferreyra L, et al. SAT0427 ASAS Health Index: validity and reliability in Argentinean patients with spondyloarthritis. Ann Rheum Dis 2017;76:933.
XL. Martire MV, Girard Bosch P, Airoldi C, Benegas M, Cosentino V, Duarte V, et al. Rendimiento del ASAS Health Index en pacientes con Espondiloartritis de la vida real. Rev Argent Reumatol. 2021;32(2):9-15.
XLI. Molto A, López-Medina C, Van den Bosch FE, Boonen A, Webers C, Dernis E, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021;80(11):1436-1444.
XLII. Schneeberger EE, Marengo MF, Dal Pra F, Maldonado Cocco JA, Citera G. Fatigue assessment and its impact in the quality of life of patients with ankylosing spondylitis. Clin Rheumatol. 2015;34(3):497-501.
XLIII. Schentag C, Cichon J, MacKinnon A, Gladman D, Urowitz MB. Validation and normative data for the 0-10-point scale version of the fatigue severity scale (FSS). Arthritis Rheum 2000;3(Suppl):S177.
XLIV. Cella D, Lenderking WR, Chongpinitchai P, Bushmakin AG, Dina O, Wang L, et al. Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. J Patient Rep Outcomes. 2022;23;6(1):100.
XLV. Webers C, Vanhoof L, Leue C, Boonen A, Köhler S. Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study. Arthritis Res Ther. 2019;21(1):215.
XLVI. Barlow JH, Macey SJ, Struthers GR. Gender, depression and ankylosing spondylitis. Arthritis Care Res 1993;6:45-51.
XLVII. Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford). 2006;45(10):1288-93.
XLVIII. İzci Duran T, Pamukçu M, Ulusoy H, Altınbaş K. Evaluation of the role of affective temperamental features, automatic thoughts, and symptom interpretation on disease activity in patients with axial spondyloarthritis. Alpha Psychiatry. 2023;1;24(2):68-74.
XLIX. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67(6):361-70.
L. Chan CYY, Tsang HHL, Lau CS, Chung HY. Prevalence of depressive and anxiety disorders and validation of the Hospital Anxiety and Depression Scale as a screening tool in axial spondyloarthritis patients. Int J Rheum Dis. 2017 Mar;20(3):317-325.
LI. Albanesi de Nasetta S, Vázquez GH. Aspectos sociodemográficos de la evaluación de los temperamentos afectivos según la escala TEMPS-A en la Argentina [Socio-demographic aspects of the temperaments evaluation according the Argentine TEMPS-A]. Vertex. 2007 Jul-Aug;18(74):272-9.
LII. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.
LIII. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Henning Z, et al. The early disease stage in axial spondylarthritis: results from the German spondyloarthritis inception cohort. Arthritis Rheum 2009;60(3):717-727.
LIV. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006;78(33):4-11.
LV. Haywood KL, Garratt AM, Dziedzic K, Dawes PT. Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index. J Rheumatol 2003;30(4):764-773.
LVI. Boonen A, Chorus A, Miedema H, van der Heijde D, Landewé R, Schouten H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033-1039.
LVII. Molto A, Tezenas du Montcel S, Wendling D, Dougados M, Vanier A, Gossec L. Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. Ann Rheum Dis 2016;76(6):1036-1041.
LVIII. Tran-Duy A, Nguyen TT, Thijs H, Baraliakos X, Heldmann F, Braun J, et al. Longitudinal analyses of presenteeism and its role as a predictor of sick leave in patients with ankylosing spondylitis. Arthritis Care Res 2015;67(11):1578-1585.
LIX. van der Weijden MA, Boonen A, van der Horst-Bruinsma IE. Problems in work participation and resource use should not be underestimated in patients with early spondyloarthritis. J Rheumatol 2014;41(12):2413-2420.
LX. Macfarlane GJ, Shim J, Jones GT, et al. Identifying persons with axial spondyloarthritis at risk of poor work outcome: results from the British Society for Rheumatology Biologics Register Gary J. J Rheumatol 2019;46(2):145-152.
LXI. Marengo MF, Schneeberger EE, Citera G, Maldonado Cocco JA. Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 2008;14(5):273-277.
LXII. Airoldi C, Martire MV, Girard Bosch P, Benegas M, Duarte V, Cosentino V, et al. Participación laboral en espondiloartritis axial radiográfica y no radiográfica. Rev Argent Reumatol. 2021;32(4):12-20.
LXIII. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford) 2010;49(4):812-819.
LXIV. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis. 1987;46(3):197-202.
LXV. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van ver Tempel H, Mielants H,et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62(2):127-32.
LXVI. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948-53.
LXVII. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;15;59(5):686-91.
LXVIII. Polachek A, Li S, Chandran V, Gladman DD. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort. Incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken). 2017;69(11):1685-1691.
LXIX. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner D. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;9(32):1745-50.
LXX. Navarro-Compán V, Boel A, Boonen A, Mease PJ, Dougados M, Kiltz U, et al. Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Ann Rheum Dis. 2023;82(6):763-772.
Derechos de autor 2024 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
